This webinar, brought to you by Fujifilm Biosciences, will be hosted live and available on-demand.
Thursday, February 18th, 2026
11:00 AM - 12:00 PM ET
T-cell engineering involves a series of interconnected processes that can influence the characteristics and performance of cells used in therapeutic research. Decisions involving activation, culture conditions, genetic modification, and viral vector preparation can affect cell viability, phenotype, and workflow consistency. Optimizing these steps independently may overlook important interactions between processes, highlighting the need to evaluate T-cell engineering as a connected workflow.
In this webinar, brought to you by FUJIFILM Biosciences, Yosuke Kurokawa, PhD, will discuss strategies for optimizing critical stages of T-cell engineering, from activation and expansion to gene delivery and lentiviral vector purification. He will explore considerations for maintaining less-differentiated T-cell characteristics during expansion, selecting chemically defined culture conditions, and evaluating viral and nonviral gene delivery approaches. Kurokawa will also examine technologies designed to support these workflows, including StemGuard T Cell Activator, PRIME-XV T Cell CDM, F-lexLNP Ready-to-Use Lipid Nanoparticle Reagent Kit, and PS Capture Envelope Virus Purification Kit.
Attendees will:
- Examine how decisions across T-cell activation, expansion, gene delivery, and vector preparation can influence downstream cell characteristics and workflow performance.
- Explore how activation strategies and culture conditions may affect T-cell proliferation, phenotype, and expansion.
- Compare considerations for viral and nonviral gene delivery approaches in T-cell engineering.
- Evaluate strategies for integrating T-cell culture, genetic modification, and lentiviral vector purification into more controlled workflows
![]() | Yosuke Kurokawa |

















